Literature DB >> 26405586

miR-155 releases the brakes on antitumor T cells.

Yun Ji1, Luca Gattinoni1.   

Abstract

Homeostatic γC cytokines are essential to support the expansion and function of tumor-specific T cells, but their effects are constrained by suppressor of cytokine signaling (SOCS) proteins as well as phosphoinositide and tyrosine-specific phosphatases. The microRNA miR-155 counteracts these inhibitory hurdles to potentiate intracellular cytokine signaling and T cell antitumor immunity.

Entities:  

Keywords:  Ptpn2; SHIP-1; SOCS-1; adoptive immunotherapy; homeostatic γC cytokines; lymphodepletion; miR-155

Year:  2015        PMID： 26405586      PMCID： PMC4570134          DOI： 10.1080/2162402X.2015.1026533

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Negative regulation of cytokine signaling pathways.

Authors:  H Yasukawa; A Sasaki; A Yoshimura
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

Authors:  Sid P Kerkar; Pawel Muranski; Andrew Kaiser; Andrea Boni; Luis Sanchez-Perez; Zhiya Yu; Douglas C Palmer; Robert N Reger; Zachary A Borman; Ling Zhang; Richard A Morgan; Luca Gattinoni; Steven A Rosenberg; Giorgio Trinchieri; Nicholas P Restifo
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

Review 3.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

4.  A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy.

Authors:  Hyun-Il Cho; Eduardo Reyes-Vargas; Julio C Delgado; Esteban Celis
Journal:  Cancer Res       Date:  2012-02-24       Impact factor: 12.701

Review 5.  Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Authors:  Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah E Citrin; Steven A Rosenberg; Richard Childs; Nicholas P Restifo
Journal:  Nat Clin Pract Oncol       Date:  2006-12

6.  miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.

Authors:  Yun Ji; Claudia Wrzesinski; Zhiya Yu; Jinhui Hu; Sanjivan Gautam; Nga V Hawk; William G Telford; Douglas C Palmer; Zulmarie Franco; Madhusudhanan Sukumar; Rahul Roychoudhuri; David Clever; Christopher A Klebanoff; Charles D Surh; Thomas A Waldmann; Nicholas P Restifo; Luca Gattinoni
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

7.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

8.  Inositol phosphatase SHIP1 is a primary target of miR-155.

Authors:  Ryan M O'Connell; Aadel A Chaudhuri; Dinesh S Rao; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

9.  MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer.

Authors:  Jan C Dudda; Bruno Salaun; Yun Ji; Douglas C Palmer; Gwennaelle C Monnot; Estelle Merck; Caroline Boudousquie; Daniel T Utzschneider; Thelma M Escobar; Rachel Perret; Stefan A Muljo; Michael Hebeisen; Nathalie Rufer; Dietmar Zehn; Alena Donda; Nicholas P Restifo; Werner Held; Luca Gattinoni; Pedro Romero
Journal:  Immunity       Date:  2013-04-18       Impact factor: 31.745

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307
  10 in total
  2 in total

Review 1.  Non-coding RNAs in CD8 T cell biology.

Authors:  Alexandria C Wells; Elena L Pobezinskaya; Leonid A Pobezinsky
Journal:  Mol Immunol       Date:  2020-02-18       Impact factor: 4.407

2.  miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate.

Authors:  Yun Ji; Jessica Fioravanti; Wei Zhu; Hongjun Wang; Tuoqi Wu; Jinhui Hu; Neal E Lacey; Sanjivan Gautam; John B Le Gall; Xia Yang; James D Hocker; Thelma M Escobar; Shan He; Stefania Dell'Orso; Nga V Hawk; Veena Kapoor; William G Telford; Luciano Di Croce; Stefan A Muljo; Yi Zhang; Vittorio Sartorelli; Luca Gattinoni
Journal:  Nat Commun       Date:  2019-05-14       Impact factor: 14.919
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.